Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith

Patent metadata

Field	Value
Publication number	US-10137194-B2
Application number	US-201715591386-A
Country	US
Kind code	B2
Filing date	May 10, 2017
Priority date	Mar 14, 2013
Publication date	Nov 27, 2018
Grant date	Nov 27, 2018

Abstract

Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such asbovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.

First claim

We claim:

1. An immunogenic peptide conjugate consisting of a hemagglutinin fusion initiation region (FIR) peptide or a variant thereof, conjugated to an immunogenic carrier protein by a linking group; wherein the hemagglutinin FIR peptide consists of 16 amino acid residues and has an amino acid sequence that consists of SEQ ID NO: 1 or a variant of SEQ ID NO: 1 sharing at least 50% sequence identity therewith and differing from SEQ ID NO: 1 by one or more amino acid substitutions selected from the group consisting of V1I, V1L, V1A, V1G, V1T, V1S, V1M, E2D, E2K, E2R, D3E, T4G, T4S, T4Q, T4A, K5F, K5M, K5I, K5V, K5L, K5A, I6L, I6V, I6A, I6T, I6S, I6Q, I6N, D7E, L8I, L8V, L8A, W9Y, S10T, S10G, S10A, S10M, and E14K; wherein the immunogenic carrier protein is selected from the group consisting of the outer membrane protein complex of Neiserria meningitidis (OMPC), tetanus toxoid protein, diphtheria toxin derivative CRM 197 , Concholepas concholepas hemocyanin (CCH), hepatitis B virus (HBV) surface antigen protein (HBsAg), HBV core antigen protein, a rotavirus capsid protein, bovine papilloma virus (BPV) L1 protein, a human papilloma virus (HPV) L1 protein, ovalbumin, and a full-length influenza hemagglutinin protein; and wherein the linking group comprises a sulfide bond or a 4-(N-succinimidomethyl)cyclohexane-1-carbonyl group of Formula (I):

wherein a primary amine on the carrier protein is bound by an amide bond to the 1-carbonyl moiety of the 4-(N-succinimidomethyl)cyclohexane-1-carbonyl group, and the Cys residue in Formula (I) is bound by peptide bond to the to the N-terminus of the FIR peptide, optionally with an additional spacer peptide of 1 to 5 residues between the Cys and the FIR peptide.

2. The peptide conjugate of claim 1 , wherein the immunogenic carrier protein is a full-length influenza hemagglutinin protein.

3. The peptide conjugate of claim 2 , wherein the full-length influenza hemagglutinin protein is a hemagglutinin from an influenza A subtype selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16 and H17.

4. The peptide conjugate of claim 2 , wherein the full-length influenza hemagglutinin protein is an influenza B hemagglutinin protein.

5. An immunogenic peptide conjugate consisting of a hemagglutinin fusion initiation region (FIR) peptide that consists of 16 amino acid residues and has an amino acid sequence that consists of SEQ ID NO: 1, conjugated to an immunogenic carrier protein by a linking group; wherein the immunogenic carrier protein is selected from the group consisting of the outer membrane protein complex of Neiserria meningitidis (OMPC), tetanus toxoid protein, diphtheria toxin derivative CRM 197 , Concholepas concholepas hemocyanin (CCH), hepatitis B virus (HBV) surface antigen protein (HBsAg), HBV core antigen protein, a rotavirus capsid protein, bovine papilloma virus (BPV) L1 protein, a human papilloma virus (HPV) L1 protein, ovalbumin, and a full-length influenza hemagglutinin protein; and wherein the linking group is a 4-(N-succinimidomethyl)cyclohexane-1-carbonyl group of Formula (I):

wherein a primary amine on the carrier protein is bound by an amide bond to the 1-carbonyl moiety of the 4-(N-succinimidomethyl)cyclohexane-1-carbonyl group, and the Cys residue in Formula (I) is bound by peptide bond to the to the N-terminus of the FIR peptide, optionally with an additional spacer peptide of 1 to 5 residues between the Cys and the FIR peptide.

6. The peptide conjugate of claim 5 , wherein the immunogenic carrier protein is a full-length influenza hemagglutinin protein.

7. The peptide conjugate of claim 6 , wherein the full-length influenza hemagglutinin protein is a hemagglutinin from an influenza A subtype selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16 and H17.

8. The peptide conjugate claim 6 , wherein the full-length influenza HA protein is an influenza B hemagglutinin protein.

9. A pharmaceutical composition for treating or preventing an influenza infection comprising the immunogenic peptide conjugate of claim 1 in a pharmaceutically acceptable carrier.

10. A method of treating an influenza infection comprising administering a therapeutically effective amount of the immunogenic peptide conjugate of claim 1 to a subject.

11. A method of inducing a specific therapeutic antibody response in a subject comprising administering the immunogenic peptide conjugate of claim 1 to the subject.

12. The method of claim 11 , wherein the specific therapeutic antibody response is inhibiting fusion of an influenza virus with the membrane of a host cell.

13. A pharmaceutical composition for treating or preventing an influenza infection comprising the immunogenic peptide conjugate of claim 5 in a pharmaceutically acceptable carrier.

14. A method of treating an influenza infection comprising administering a therapeutically effective amount of the immunogenic peptide conjugate of claim 5 to a subject.

15. A method of inducing a specific therapeutic antibody response in a subject comprising administering the immunogenic peptide conjugate of claim 5 to the subject.

16. The method of claim 15 , wherein the specific therapeutic antibody response is inhibiting fusion of an influenza virus with the membrane of a host cell.

Assignees

• The Administrators Of The Tulane Educational Fund
• Autoimmune Tech Llc
• The Admininstrators of the Tulane Educational Fund
• Autoimmune Tech Llc

Inventors

• Garry Robert Francis
• Wilson Russell B

Classifications

• A61P31/16

  for influenza or rhinoviruses · CPC title

• C07K16/108

  Orthomyxoviridae (F), e.g. influenza virus · CPC title

• C12N2760/16122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title